Skip to main content

Lifeward Ltd.

corporate_fare Company Profile

Lifeward Ltd.

LFWD·NASDAQ·Industrial Applications And Services·CIK 0001607962

ReWalk is a medical device company that designs, develops, and commercializes solutions for physical rehabilitation and recovery. The company's initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices, referred to as SCI Products, for individuals with spinal cord injury. These robotic exoskeletons use patented tilt-sensor technology, an onboard computer, and motion sensors to power motorized legs, enabling individuals with paraplegia to stand and walk. In March 2023, ReWalk received 510(k) clearance from the U.S. FDA for the ReWalk Personal Exoskeleton with stair and curb functionality, allowing U.S. users to navigate stairs and curbs. This feature has been available in Europe since initial CE Clearance, supported by real-world data from 47 European users over seven years, involving over 18,000 stair steps. In March 2025, the company received 510(k) clearance for the ReWalk 7 Personal Exoskeleton device, a next-generation model. ReWalk has also expanded its product offerings beyond SCI Products, including the ReStore Exo-Suit device, which began commercialization in June 2019. The ReStore is a powered, lightweight soft exo-suit designed for the rehabilitation of individuals with lower limb disabilities due to stroke. Sales of the ReStore device in the European Union ceased in May 2024.

Lifeward Ltd. (NASDAQ:LFWD) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors LFWD SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Lifeward Reports 22% Revenue Decline, 123% Net Loss Increase, and Massive Dilution from Oramed Financing; Going Concern Remains
  • Lifeward Posts Catastrophic $6.70/Share Q1 Loss, Crushing Analyst Estimates
  • Lifeward Reports Q1 Revenue Decline, Increased Net Loss, and Delays 10-Q Filing Amidst Strategic Transaction Accounting
  • Oramed Pharmaceuticals Discloses 49.9% Stake in Lifeward Ltd. Following Strategic Acquisition and Financing
  • Analysts Project Deeper Q1 Loss for Lifeward, EPS Estimate at -$1.18

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$22.03M
Net Income
-$19.91M
Diluted EPS
-$17.16
Op. Cash Flow
-$16.83M
Free Cash Flow
-$16.84M
Gross Profit
$8.43M
Operating Income
-$19.67M
Cash & Equivalents
$2.17M
Debt / Equity
0.00×
Net Margin
-90.4%
Shares Outstanding
1.52M sh
Source: 10-K · filed 2026-03-18 · accession 0001178913-26-001208
Browse all tickers starting with L →
$7.29
52-week range · as of 2026-05-20 $4.14 – $15.84
Market cap
$20.52M
Volume
13.2K (1.3× avg)
3-mo avg 10K
Live data · 2026-06-03 16:54 UTC · Market open

show_chartPrice Chart

Loading chart...

feed LFWD - Latest Insights

LFWD
May 20, 2026, 4:24 PM EDT
Filing Type: 10-Q
Importance Score:
9
LFWD
May 15, 2026, 8:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
LFWD
May 15, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
LFWD
May 14, 2026, 5:19 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
LFWD
May 14, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
LFWD
Apr 27, 2026, 5:00 PM EDT
Filing Type: S-3
Importance Score:
9
LFWD
Apr 23, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
LFWD
Mar 31, 2026, 8:33 AM EDT
Source: Wiseek News
Importance Score:
8
LFWD
Mar 31, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
LFWD
Mar 25, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
LFWD
Mar 25, 2026, 4:10 PM EDT
Source: GlobeNewswire
Importance Score:
9
LFWD
Mar 20, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
LFWD
Mar 18, 2026, 11:43 AM EDT
Filing Type: 10-K
Importance Score:
9
LFWD
Mar 18, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
9
LFWD
Mar 18, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
LFWD
Mar 13, 2026, 8:16 AM EDT
Filing Type: 8-K
Importance Score:
8
LFWD
Mar 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
LFWD
Mar 11, 2026, 8:23 AM EDT
Source: Wiseek News
Importance Score:
7
LFWD
Mar 11, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
LFWD
Mar 03, 2026, 8:55 AM EST
Source: Reuters
Importance Score:
7